Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115639) titled 'Efficacy of Guselkumab in Chinese participants with Crohn's Disease following loss of response to Ustekinumab' on Dec. 29, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital,Sun Yat-sen University

Condition: Crohn's Disease

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2025-12-30

Target Sample Size: Experimental group:78;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=303074

Published by HT Digital Content Services with permission from Health Daily Digest....